TNYA — Tenaya Therapeutics Cashflow Statement
0.000.00%
Annual cashflow statement for Tenaya Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -72.7 | -124 | -124 | -111 | -90.6 |
| Depreciation | |||||
| Non-Cash Items | 4.21 | 13.6 | 19 | 20.1 | 16.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 4.74 | -0.849 | -5.65 | -7.93 | -2.46 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -60.8 | -104 | -102 | -90.5 | -68.3 |
| Capital Expenditures | -25.1 | -20.6 | -1.24 | -1.02 | -0.618 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -213 | 104 | 50 | 2.16 | 56.7 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -239 | 83.7 | 48.7 | 1.13 | 56.1 |
| Financing Cash Flow Items | 0.087 | 0 | 3.37 | — | 0.912 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 209 | 77.8 | 4.05 | 47.7 | 108 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -90.4 | 57 | -49.3 | -41.6 | 96.2 |